Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
NCT ID NCT07661420
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treatment schedule is feasible and safe, not yet to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Locations
-
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
211At-MABG (a radioactive drug that targets cancer cells)
What this could lead to
If it works, this could lead to a new treatment option for people with advanced neuroendocrine cancers that have stopped responding to other therapies.
What could go wrong
This is a very early phase 1 trial with only 16 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects from radiation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.